Alacizumab pegol

{{Short description|Pharmaceutical drug}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 477315023

| image =

| type = mab

| mab_type = F(ab')2

| source = zu/o

| target = VEGFR2

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 934216-54-3

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = ZL9780F883

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| chemical_formula =

| molecular_weight =

}}

Alacizumab pegol is an antineoplastic agent. Chemically, it is a pegylated F(ab')₂ fragment of a monoclonal antibody.[https://www.who.int/medicines/services/inn/RL60prepublication.pdf International Nonproprietary Names for Pharmaceutical Substances (INN)], World Health Organization.